Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

Understanding the Risk of Left Ventricular Thrombus After Heart Attack

Anterior ST-segment elevation myocardial infarction (STEMI) represents one of the most severe forms of heart attack, often resulting in significant damage to the heart muscle. When the anterior wall of the left ventricle is compromised, the heart’s ability to pump blood efficiently is diminished, often leading to a state known as akinesia or dyskinesia. This lack of movement creates a stagnant pool of blood within the heart’s apex, fulfilling one of the criteria of Virchow’s triad for clot formation: stasis. Historically, the development of a left ventricular (LV) thrombus has been a common and dangerous complication of anterior STEMI, significantly increasing the risk of systemic embolism and ischemic stroke. Despite advances in reperfusion strategies such as primary percutaneous coronary intervention (PCI), the incidence of LV thrombus remains a concern for clinicians worldwide.

The Rationale Behind the APERITIF Trial

The standard of care for patients following a STEMI involves dual antiplatelet therapy (DAPT), typically consisting of aspirin and a P2Y12 inhibitor like ticagrelor or clopidogrel. While DAPT is highly effective at preventing stent thrombosis and recurrent ischemic events, its efficacy in preventing the formation of large clots within the ventricular cavity is less clear. Oral anticoagulants (OACs), such as warfarin or direct oral anticoagulants (DOACs) like rivaroxaban, are the primary treatment for established thrombi. This led researchers to question whether the prophylactic addition of a low-dose anticoagulant to the standard DAPT regimen could prevent the thrombus from forming in the first place without excessively increasing the risk of major bleeding. The APERITIF trial (Anticoagulant Prophylaxis for Every Real-world Infarction with Thrombus In Formation) was designed to address this clinical uncertainty.

Study Design and Methodology

The APERITIF trial was a multicenter, open-label, randomized clinical trial with a blinded-end point design conducted across 29 medical centers in France. The trial was nested within the FRENCHIE (French Cohort of Myocardial Infarction Evaluation) registry, ensuring a robust and well-documented patient population. Between October 2021 and January 2023, 560 patients with anterior STEMI were enrolled. To be included, patients had to have undergone successful primary PCI or angiography and be considered at risk for LV thrombus. The primary endpoint of the study was the presence of an LV thrombus detected via contrast-enhanced cardiac magnetic resonance imaging (CMR) at the one-month mark. CMR is considered the gold standard for thrombus detection due to its high sensitivity and specificity compared to traditional echocardiography.

The Treatment Intervention

Participants were randomized into two distinct groups. The experimental group (n=283) received DAPT plus low-dose rivaroxaban (2.5 mg twice daily) for a duration of four weeks. This specific dose was chosen based on previous successes in the COMPASS and ATLAS ACS 2–TIMI 51 trials, which suggested that low-dose rivaroxaban could provide cardiovascular protection with a manageable bleeding profile. The control group (n=277) received DAPT alone, consisting of aspirin (≤100 mg daily) and either clopidogrel (75 mg daily) or ticagrelor (90 mg twice daily). The intervention began as soon as possible after the initial cardiac procedure.

Analyzing the Results

The results of the APERITIF trial provided critical insights into the limitations of triple therapy in this context. At the one-month follow-up, an LV thrombus was detected in 13.7% of the rivaroxaban group (38 patients) compared to 16.6% of the DAPT-only group (47 patients). The difference of -2.9% was not statistically significant (P = 0.34). Furthermore, there was no observed difference between the two groups regarding the size of the thrombus or the incidence of major adverse cardiovascular events (MACE), such as recurrent heart attack or stroke. From an efficacy standpoint, the addition of rivaroxaban did not provide the clear preventive benefit that the researchers had hypothesized.

Safety Profile and Bleeding Risks

A major concern in any study involving triple therapy (two antiplatelets plus one anticoagulant) is the risk of hemorrhage. The APERITIF trial closely monitored bleeding events using the Bleeding Academic Research Consortium (BARC) criteria. The incidence of major bleeding (BARC type 2 or higher) was low and comparable between both groups (1.5% in the rivaroxaban group vs 0.7% in the DAPT group). However, minor bleeding events (BARC type 1) occurred significantly more frequently in the group receiving rivaroxaban (16.4% vs 7.2%). While minor bleeding does not usually result in long-term disability, it can lead to decreased patient compliance and increased healthcare utilization, making it a relevant factor in clinical decision-making.

Clinical Implications and Discussion

The findings of the APERITIF trial suggest that the routine addition of low-dose rivaroxaban to DAPT for the prevention of LV thrombus after anterior STEMI may not be warranted for all patients. The researchers noted that the study might have been underpowered to detect a very modest benefit, but the data clearly indicates that the preventive effect is not as robust as hoped. Several factors may contribute to these results. Modern DAPT, particularly with potent agents like ticagrelor, already provides significant antithrombotic protection. Additionally, the four-week window for rivaroxaban treatment might have been too short, or the 2.5 mg dose might have been insufficient to counteract the high thrombogenicity of the akinetic apex in the early post-MI phase.

Conclusion and Future Directions

In conclusion, the APERITIF trial demonstrated that adding 2.5 mg of rivaroxaban twice daily to DAPT did not statistically reduce the incidence of LV thrombus at one month but did increase the rate of minor bleeding. For clinicians, this means that the decision to use anticoagulation in the absence of a confirmed thrombus should be highly individualized, taking into account the patient’s specific bleeding risk and the extent of ventricular damage. Future research may focus on identifying higher-risk subgroups who might derive more benefit from this strategy or investigating different dosing regimens. For now, standard DAPT remains the cornerstone of therapy, with close monitoring via imaging for those at high risk of clot formation.